Marta J Llorca-Cardenosa, Lauren I Aronson, Dragomir B Krastev, Jadwiga Nieminuszczy, John Alexander, Feifei Song, Malgorzata Dylewska, Ronan Broderick, Rachel Brough, Astrid Zimmermann, Frank T Zenke, Bora Gurel, Ruth Riisnaes, Ana Ferreira, Theodoros Roumeliotis, Jyoti Choudhary, Stephen J Pettitt, Johann de Bono, Andres Cervantes, Syed Haider, Wojciech Niedzwiedz, Christopher J Lord, Irene Y Chong
Gastric cancer represents the third leading cause of global cancer mortality and an area of unmet clinical need. Drugs that target the DNA damage response, including ATR inhibitors (ATRi), have been proposed as novel targeted agents in gastric cancer. Here, we sought to evaluate the efficacy of ATRi in preclinical models of gastric cancer and to understand how ATRi resistance might emerge as a means to identify predictors of ATRi response. A positive selection genome-wide CRISPR-Cas9 screen identified candidate regulators of ATRi resistance in gastric cancer...
October 23, 2022: Cancer Research